Abstract:Objective To investigate the safety and clinical efficacy of microparticle transcatheter arterial chemoembolization (mTACE) combined with surgical resection for the treatment of huge hepatocellular carcinoma (hHCC; ≥ 10 cm). Methods A retrospective descriptive study was conducted to gather the clinical data of nine patients with hHCCs treated with mTACE combined with resection in Beijing Tsinghua Changgung Hospital from December 2016 to July 2020. The outcome were as follows: (1) the excellent effect and adverse reactions of mTACE and (2) the efficacy and safety of perioperative resection. Count data were expressed as absolute numbers and percentages. The measurement data of the normal distribution is represented by X ± S, and the measurement data of the skewed distribution are represented by M (range). A paired t-test was used to compare the data of the same patient. p values <0.05 are considered statistically significant. Results (1) Regarding the efficacy and safety of mTACE, all nine hHCCs were treated with mTACE one time. The tumor necrosis rate after particle TACE was (77.6 ± 15.7)% (51.7%–100%); according to the modified response evaluation criteria in solid tumors, the objective response was partial response in eight patients and complete response in one patient. The alpha fetoprotein (AFP) level was abnormal in six cases (>20 ng/mL), of which three cases exceeded the maximum value (>30,000 ng/mL) pre-mTACE. In six patients with abnormal AFP levels, the AFP level decreased in five patients, with a median percentage of 74.5% (35.2%–96.0%). The PIVKA-II level in nine patients was > 40 mAU/mL before mTACE and decreased to varying degrees after mTACE. The median percentage of decline was 76.0% (4.5%–99.8%). The maximum diameter of the tumor decreased from (13.9 ± 1.9) cm (11.0–16.4 cm) to (12.8 ± 1.9) cm (10.4–15.6 cm) (P = 0.001) before surgical resection. Prior to the surgical resection, the tumor volume decreased from (897 ± 244) mL (436–1250 mL) to (750 ± 291) mL (260–1130 mL) (P = 0.001), and the residual liver volume/standard liver volume increased from (42.8 ± 12.8)% (25.8%–61.3%) to (50.2 ± 14.9)% (28.8%–67.4%) (P = 0.008). All patients had embolism syndrome such as fever and abdominal pain in varying degrees, and no serious complications such as liver abscess, liver and kidney failure, or ectopic embolism were noted. (2) For perioperative efficacy and safety, all lesions were successfully resected in (31 ± 11) days (14–48 days) after mTACE. The operation time was (395 ± 79) min (296–540 min), and the amount of intraoperative bleeding was (433 ± 158) mL (200–600 mL). Complications such as biliary fistula, abdominal bleeding, liver and kidney failure, or abdominal infection were not found. The postoperative hospital stay was (13 ± 4) days (9–19 days). No tumor invasion was found at the cutting edge, and hepatic vein invasion was observed in one case. (3) The follow-up ended in November 2021, with a median follow-up of 34 months (16–46 months). Recurrence or distant metastasis occurred in four patients, of which two patients died. The survival times were 18 and 31 months, respectively. The other two patients were followed up for 34 and 41 months. The remaining five patients were followed up for 16–46 months without antitumor treatment or disease progression. Conclusions mTACE combined with tumor resection is feasible for the treatment of patients with hHCC, which needs to be further confirmed by prospective studies.

Interventional chemoembolization with hepasphere-loaded microspheres for the treatment of unresec-table hepatocellular carcinoma:preliminary results in 15 cases

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

Safety And Efficacy Of Drug-Eluting Bead Transarterial Chemoembolization With Callispheres (R) Microsphere For Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Preliminary Study

Transhepatic Arterial Chemoembolization by Epirubicin Mixed with Microspheres for Hepatocellular Carcinoma

Chemoembolization of Liver Cancer with Drug-Loading Microsphere 50-100Μm

[Clinical Investigation on Transarterial Chemoembolization with Indigenous Drug-Eluting Beads in Treatment of Unresectable Hepatocellular Carcinoma].

Efficacy And Safety Of Drug-Eluting Beads Transarterial Chemoembolization By Callispheres (R) In 275 Hepatocellular Carcinoma Patients: Results From The Chinese Callispheres (R) Transarterial Chemoembolization In Liver Cancer (Ctilc) Study

Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer

Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma.

A new thermosensitive embolic agent used for arterial embolization of primary hepatocellular carcinoma:preliminary clinical trial

Simultaneous CSM‐TACE with CalliSpheres® and partial splenic embolization using 8spheres® for hepatocellular carcinoma with hypersplenism: Early prospective multicenter clinical outcome

Exploratory Study of Microparticle Transcatheter Arterial Chemoembolization Combined with Resection for Huge Hepatocellular Carcinoma

Clinical Efficacy of Transcatheter Arterial Chemoembolization Combined With Percutaneous Microwave Coagulation Therapy for Advanced Hepatocellular Carcinoma

Preliminary Clinical Study of Transcatheter Arterial Chemoembolization with ContourSe Microspheres and Lipiodol in Patients with Large Hepatocellular Carcinoma

Safety and efficacy of drug-eluting bead transarterial chemoembolization with CalliSpheres® microsphere for hepatocellular carcinoma with portal vein tumor thrombus: a preliminary study

Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma

Oxaliplatin and 5-Fluorouracil Hepatic Infusion with Lipiodolized Chemoembolization in Large Hepatocellular Carcinoma.

Efficacy of transarterial chemoembolization treatment with 30-60-μm microspheres in patients with hepatocellular carcinoma